Analysts have slightly lowered their price target for Integrated Diagnostics Holdings from $0.82 to $0.80. This change is due to marginal adjustments in fair value estimates as a result of updated financial forecasts.
What's in the News
- Integrated Diagnostics Holdings plc has issued new earnings guidance for the full year 2025 (Key Developments).
- The company expects revenue growth to exceed 30% in 2025 (Key Developments).
Valuation Changes
- Fair Value Estimate: Decreased slightly from $0.82 to $0.80.
- Discount Rate: Remained unchanged at 7.07%.
- Revenue Growth Forecast: Virtually unchanged at approximately 19%.
- Net Profit Margin: Stable with a negligible decrease from 20.06% to 20.06%.
- Future P/E Ratio: Marginally decreased from 12.05x to 11.93x.
Have other thoughts on Integrated Diagnostics Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.